Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 38

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

427

HTML

4116

Figures (1-3)

273

Tables (1-3)

207

Sum=5023

Oct 14, 2010 (publication date) through Nov 20, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 14, 2010; 16(38): 4823-4831
Published online Oct 14, 2010. doi: 10.3748/wjg.v16.i38.4823

Full Size Figure Download Figure

Figure 2 Overview of classification rates for various combinations of features. EGFR: Epidermal growth factor receptor.

Citation: Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S, Vlajnic T, Frattini M, Lugli A. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol 2010; 16(38): 4823-4831
URL: https://www.wjgnet.com/1007-9327/full/v16/i38/4823.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i38.4823